There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the
pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor …

Background For patients with metastatic colorectal cancer, stratification for treatment
(surgery or chemotherapy) is often based on crude clinicopathological characteristics like …

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by
malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Background In non-metastatic colorectal cancer (CRC), we evaluated prospectively the
pertinence of longitudinal detection and quantification of circulating tumor DNA (ctDNA) as a …

Background: Colorectal cancer is one of the most common cancers worldwide and has a
high mortality rate following disease recurrence. Treatment efficacy is maximized by …

Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …

The application of circulating tumor DNA (ctDNA) represents a non-invasive method for
tumor detection. Its prognostic significance in patients with colorectal cancer is controversial …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …